AUTHORS
Naveen Pemmaraju, MD, Giovanni Marconi, MD2, Pau Montesinos, MD3, Andrew A. Lane, MD, PhD4, Luca Mazzarella5, David Sallman, MD6, Matthew L. Ulrickson, MD7, Gary J. Schiller, MD8, Harry P. Erba, MD9, Eunice Sue Wang, MD10, Roland Bruno Walter, MD, PhD, MS11, Eric Deconinck, MD, PhD12, Ahmed Aribi, MD13, Ollivier Legrand, MD14, Delphine Lebon, MD, PhD15, Giovanni Martinelli, MD16, Daniel J DeAngelo, MD, PhD17, Nisha Kishore, PharmD18, Yulei He19, Shilpa Jain20, Jalaja Potluri, MD21, Naval Daver, MD22
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
2 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRST S.r.l., Meldola, Italy
3 Hospital Universitari i Politècnic La Fe, Valencia, Spain
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 European Institute of Oncology IRCCS, Milano, Italy
6 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
8 David Geffen School of Medicine at UCLA, Los Angeles, California, United States
9 Duke University, Durham, North Carolina, United States
10 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States
12 CHU Besançon-Hématologie, Besançon, France
13 City of Hope, Duarte, California, United States
14 Hospital St. Antoine, Paris, France
15 CHU Picardie, Aimens, France
16 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRST S.r.l., Meldola, Italy
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 AbbVie, Inc., North Chicago, Illinois, United States
19 AbbVie, Inc., North Chicago, Illinois, United States
20 AbbVie, Inc., North Chicago, Illinois, United States
21 AbbVie, Inc., North Chicago, Illinois, United States
22 MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Introduction: BPDCN, is a rare and aggressive hematologic malignancy characterized by CD123 overexpression. Often, the goal of treatment is to induce a deep and rapid response to enable hematopoietic stem cell transplantation (HSCT), which remains the only potentially curative option. PVEK (Decnupaz) is the first-in-class and only CD123-targeted antibody-drug conjugate that is Food and Drug Administration-approved for adult patients with BPDCN that can be initiated in an outpatient setting. In CADENZA (NCT03386513), PVEK demonstrated durable and high response rates, with 39% of 1L patients bridged to HSCT. We report a post-hoc analysis of PVEK efficacy in patients with 1L BPDCN stratified by age and comorbidities, such as renal and hepatic function, which are commonly used to assess overall patient fitness and HSCT eligibility.
Methods: In the phase 1/2 CADENZA study, adults with 1L BPDCN received PVEK 0.045 mg/kg intravenously (<30-min infusion) on Day 1 of a 21-day cycle. Patients were stratified based on the following fitness subgroups: age (≤70 vs >70 years), baseline renal function (normal vs mild to moderate impairment [MMI]), baseline hepatic function (normal vs MMI), and comorbidity burden; outcomes in the most fit (≤70 years with no comorbidity) vs least fit (>70 years with ≥1 comorbidity) patients were also assessed. Outcomes included complete response (CR) rate, clinical CR (CRc) rate, CR/CRc rate, duration of CR+CRc, and percentage of patients bridged to post-treatment HSCT.
Results: Of 33 patients with 1L BPDCN, 12 (36%) vs 21 (64%) were ≤70 vs >70 years of age, 13 (39%) vs 20 (61%) had normal vs MMI renal function, and 27 (82%) vs 6 (18%) had normal vs MMI hepatic function; 7 (21%) vs 18 (55%) were ≤70 years with no comorbidity vs >70 years with ≥1 comorbidity. Baseline characteristics were similar within patient subgroups.
For patients ≤70 vs >70 years of age, 75% vs 67% achieved CR+CRc (50% vs 57% CR and 25% vs 10% CRc); median duration of CR+CRc was 12.9 vs 9.5 months (12-month Kaplan-Meier [KM] estimate: 56% vs 29%); and 58% vs 29% received HSCT. For patients with normal vs MMI renal function, 77% vs 65% achieved CR+CRc (62% vs 50% CR and 15% vs 15% CRc); median duration of CR+CRc was 9.5 vs 9.9 months (12-month KM estimate: 40% vs 38%); and 46% vs 35% were bridged to HSCT. For patients with normal vs MMI hepatic function, 67% vs 83% achieved CR+CRc (52% vs 67% CR and 15% vs 17% CRc); median duration of CR+CRc was 10.3 vs 6.8 months (12-month KM estimate: 44% vs 20%); and 44% vs 17% were bridged to HSCT. For patients who were ≤70 years with no comorbidity vs >70 years with ≥1 comorbidity, 71% vs 67% achieved CR+CRc (43% vs 56% CR and 29% vs 11% CRc); median duration of CR+CRc was 4.6 vs 9.4 months (12-month KM estimate: 40% vs 25%); and 57% vs 28% were bridged to HSCT.
Safety data for the full 1L cohort has been reported previously. Veno-occlusive disease occurred in 3 patients; 2 on-treatment events (median time to onset of 131 days) that resolved after PVEK discontinuation (d/c), and 1 fatal post-HSCT event in a patient that received busulfan-based conditioning prior to HSCT. PVEK dose reductions due to AEs occurred in 1 (8%) vs 2 (10%) patients ≤70 vs >70 years of age; 2 (15%) vs 1 (5%) patients with normal vs MMI renal function; 0 vs 3 (50%) patients with normal vs MMI hepatic function; and 0 vs 2 (11%) patients who were ≤70 years with no comorbidity vs >70 years with ≥1 comorbidity. PVEK d/c due to AEs occurred in 3 (25%) vs 3 (14%) patients ≤70 vs >70 years of age; 3 (23%) vs 3 (15%) patients with normal vs MMI renal function; 4 (15%) vs 2 (33%) patients with normal vs MMI hepatic function; and 1 (14%) vs 3 (17%) patients who were ≤70 years with no comorbidity vs >70 years with ≥1 comorbidity.
Additional analyses stratifying patients by baseline fitness status using the Charlson Comorbidity Index will be presented.
Conclusions: Independent of baseline fitness status, patients with 1L BPDCN treated with PVEK achieved deep responses, with high overall response rates across all subgroups, enabling many patients to proceed to post-treatment HSCT. Across patient subgroups, PVEK d/c due to AEs were consistent with what was previously reported.
DISCLOSURES
Naveen Pemmaraju, MD: HemOnc Times/Oncology Times - Other (including travel support); Physician’s Education Resource - Honoraria; MDEducation - Honoraria; PVEK - Honoraria; Indy Hematology Education - Honoraria; Synapse Medical Communications - Honoraria; Takeda - Research Funding; Johnson & Johnson - Research Funding; US Department of Defense - Research Funding; AbbVie - Research Funding; Institutional funding from US Department of Defense - Research Funding; Meiji - Research Funding; Opna bio LLC - Research Funding; National Institutes of Health/National Cancer Institute (NIH/NCI) - Research Funding; Karyopharm Therapeutics - Research Funding; Sager Strong Foundation - Research Funding; Incyte - Research Funding; Menarini-Stemline Therapeutics - Research Funding; Disc Medicine - Research Funding; Karger Publishers - Patents & Royalties; ASH Committee on Communications - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); Dava Oncology - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony); Menarini-Stemline Therapeutics - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Patient Power - Consultancy (Includes expert testimony); Harborside Press - Consultancy (Includes expert testimony); Meiji - Consultancy (Includes expert testimony); Eli Lilly & Co - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Aptitude Health - Consultancy (Includes expert testimony); HemOnc Times/Oncology Times - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Aplastic Anemia and MDS International Federation - Consultancy (Includes expert testimony); Medscape - Consultancy (Includes expert testimony); CTI BioPharma Corporation - Consultancy (Includes expert testimony); MorphoSys - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Menarini Group - Consultancy (Includes expert testimony); Paylex - Consultancy (Includes expert testimony); EUSA Pharma - Consultancy (Includes expert testimony); Silence Therapeutics - Consultancy (Includes expert testimony); Cimeio Therapeutics - Consultancy (Includes expert testimony); Clearview Healthcare Partners - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); OncLive - Consultancy (Includes expert testimony); Intellisphere - Consultancy (Includes expert testimony); Magdalen Medical Publishing - Consultancy (Includes expert testimony); Curio Science - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); BeONe - Consultancy (Includes expert testimony); Dan's House of Hope - Consultancy (Includes expert testimony); Immunogen - Consultancy (Includes expert testimony); Opna bio LLC - Consultancy (Includes expert testimony); Pacylex - Consultancy (Includes expert testimony); Imedex - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Astellas Pharma - Consultancy (Includes expert testimony); Cimeio Therapeutics AG - Consultancy (Includes expert testimony); Physician’s Education Resource - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); CareDx - Consultancy (Includes expert testimony); CancerNet - Consultancy (Includes expert testimony); Neopharm - Consultancy (Includes expert testimony); ASCO Cancer.Net Editorial Board - Consultancy (Includes expert testimony); PeerView Institute for Medical Education - Consultancy (Includes expert testimony); Neopharm - Consultancy (Includes expert testimony); Cimeio Therapeutics AG - Speakers Bureau.; Paylex - Speakers Bureau.; Cimeio Therapeutics AG - Membership on a Board/Advisory Committee; Paylex - Membership on a Board/Advisory Committee; Dan’s House of Hope - Membership on a Board/Advisory Committee